Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C1323099 (sympathomimetic)
 2,957 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effect on plasma lipids of a new beta-blocker bucindolol, which possesses weak alpha-adrenergic blocking property and intrinsic sympathomimetic activity, given orally over a 3-month period as a monotherapy or with a thiazide diuretic to 44 patients with essential hypertension was studied. The mean level of plasma HDL cholesterol concentration increased significantly during 3 months monotherapy with bucindolol or with bucindolol and diuretic. This increase was due to the increase of HDL3 subfraction. There were no significant changes in the concentrations of plasma triglycerides or total cholesterol during treatment. The ratio of HDL cholesterol to total cholesterol increased significantly. The concentration of apoprotein A-I decreased significantly in both treatment groups, but the level of apoprotein B remained constant among treatment groups. The results support the earlier observations that beta-adrenergic blocking agents with different pharmacologic properties differ as regard to their effects on plasma lipids and lipoproteins.
 ...
PMID:Effect of bucindolol on plasma HDL cholesterol subfractions and other plasma lipids in essential hypertensive patients. 288 37

Several studies show that many selective and non-selective beta-adrenoceptor blocking drugs and beta-blockers with weak intrinsic sympathomimetic activity increase serum total cholesterol and triglyceride and decrease HDL-cholesterol and free fatty acid concentrations. The concentrations of serum free fatty acids and triglycerides remained about constant during twelve months treatment of hypertensive patients with pindolol. The level of HDL-cholesterol was increased after the first month of treatment, but there were no significant differences between the concentrations of HDL-cholesterol before the treatment and after three, six and twelve months of treatment. The ratio of HDL-cholesterol to total cholesterol increased from 0.18 to 0.20 during treatment, and this increase was statistically significant at six month. The concentration of apolipoprotein A-I and the ratio of A-I to apoprotein A-II increased slightly but not significantly during pindolol treatment. Lecithin cholesterol acyl-transferase activity was significantly higher during pindolol treatment than after three weeks break of treatment. Comparing the results of the study of pindolol with previous reports of other beta-blockers pindolol might have fewer untoward effects on lipid metabolism than beta-blockers without intrinsic sympathomimetic activity.
 ...
PMID:Beta-blockade and plasma lipids. 613 68

Tertatolol is a noncardioselective beta-blocker without intrinsic sympathomimetic activity. In a preliminary 3-month open study, it was shown that T was devoid of any atherogenic effect since HDL-cholesterol (HDL-C) and apoprotein levels did not change for 3 months of therapy. To investigate the long-term effects of tertatolol on the lipid profile and its safety in hypertensive patients with peripheral arterial disease (PAD), a 9-month, randomized, double-blind, parallel group study was carried out in 40 patients. Tertatolol 5 mg once daily was compared with metoprolol 200 mg once daily. If BP was not controlled after 2 months, a vasodilatator agent, dihydralazine, was added at the lowest dose required to control BP (diastolic BP < 90 mm Hg). Lipoprotein fractions and apoproteins were assayed before (M0) and after 2, 6 and 9 months of therapy. At the same occasions, peripheral arterial disease (PAD) was evaluated on exercise tests carried out on a treadmill and on the regional blood flow measured in the ankle arteries by the Doppler technique. Four patients were not eligible for analysis. In the tertatolol group, 1 patient with a normal BP, and 2 patients who dropped out, 1 because of persistent nausea and 1 because of personal reasons. In the metoprolol group, 1 patient refused to take dihydralazine. In the 35 fully documented patients, BP control was achieved in both groups. The mean reductions in supine systolic/diastolic BP were 31.4/14.6 and 34.7/17.1 mm Hg in the tertatolol and metoprolol groups, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:The effects of tertatolol on lipid profile. 790 13